HHTU News Roundup
NEWDAY-ABC Opened to recruitment
North of England Wellness through healthy fooD choices and ActivitY After early Breast Cancer (NEWDAY-ABC) opened to recruitment in October.
Building on the success of the feasibility study of the same name, NEWDAY-ABC is evaluating a support programme designed to help patients recovering from early-stage HER2-negative breast cancer. The programme aims to equip participants with the skills and confidence to make sustainable lifestyle changes, achieve a healthy weight and increase their levels of physical activity.
NEWDAY-ABC is a randomised controlled hybrid intervention-implementation trial, funded by Yorkshire Cancer Research and sponsored by the University of Hull. The Chief Investigators are Prof John Saxton and Dr Caroline Wilson, with Matt Northgraves serving as Trial Manager and Judith Horrocks leading data management.
The trial in currently open to HER2 negative breast cancer patients within 36 months of their primary diagnosis who received their treatment at the Christie NHS Foundation Trust and Hull University Teaching Hospitals Foundation Trust. With plans to open further sites across Yorkshire.
Further information for patients of the Christie NHS Foundation Trust can find more information here: https://hhtu.box.com/s/v9n6ssav0hys6gwe9p1nugnbnfewr5zr
Further information for patients of Hull University Teaching Hospitals Foundation Trust can find information here: https://hhtu.box.com/s/8aigfvy7tdvbfhba3m72xa3aadprgzel
STARLIT results meeting
The STARLIT studies were investigating the comparison between a novel formulation of tetracosactide, Nasacthin, administered intranasally in conjunction with the use of saliva samples to measure cortisol and cortisone levels, and the current routine intravenous administration of tetracosactide (using Synacthen) along with serial blood tests, to diagnose adrenal insufficiency. STARLIT-1 assessed differences in blood and saliva cortisol levels in the same individual; STARLIT-2 compared the blood sample Synacthen test to the needle-free Nasacthin test in healthy adults and children; STARLIT-3 looked at the effectiveness of the needle-free Nasacthin test in patients with adrenal insufficiency.
On 20th October 2026, the study team met up in Sheffield for a final study close out meeting where the results were presented, and the team were able to spend an afternoon reflecting on the amount of time and hard work that has been invested into this suite of studies, from a range of different people over several years, and to have a shared lunch in the process! It was a lovely few hours to spend away from the office and there were personalised thank you cards from the study’s CI to each of the people involved, which was an unexpected and welcome surprise.
Papers published
October was a productive month for publications, with four studies reaching important milestones. Two results papers were published, alongside two protocol papers outlining new and ongoing research.
1. LIPS – a registry of patients affected by leukaemia in pregnancy.
A major milestone for the trials unit was achieved with the publication of the Leukaemia in Pregnancy Study (LIPS) results paper. LIPS was one of the first studies delivered by HHTU and sought to establish a national research database for patients affected by leukaemia during and around pregnancy. The study monitored treatment approaches and pregnancy outcomes in two patient groups:
1. Patients diagnosed with acute leukaemia or high-risk myelodysplasia during pregnancy.
2. Patients who became pregnant following successful chemotherapy treatment.
Although acute leukaemia diagnosed during pregnancy is rare, it presents a potentially devastating clinical scenario and a number of unique treatment challenges. Clinicians must balance the risks to the mother of delaying urgent treatment against the potential impact of chemotherapy on fetal development and pregnancy outcomes.
Established during the COVID-19 pandemic, LIPS required a tremendous collaborative effort from a much smaller HHTU team than we have today, alongside the many participating sites that contributed valuable data. Funded by Blood Cancer UK, this work has added further evidence to improve our understanding of the complex clinical and treatment decisions faced by patients and healthcare professionals in these challenging circumstances.
2. MABEL – sub study – clinicians view on morphine use for breathlessness
Another results paper published this month came from the MABEL Sub-Study.
The main MABEL study was a large study that tested whether regular low dose morphine capsules regularly twice a day are better than a placebo for chronic breathlessness and whether this increases daily activity. The sub study investigated clinician perspectives on morphine use for chronic breathlessness. Using a mixed-methods approach based on Normalisation Process Theory, clinicians completed a Learning Needs Assessment (LNA) survey and a Modified Normalisation Measurement (NoMAD) instrument at two time points: immediately after training and four months later. The aim was to identify barriers and facilitators to implementing morphine prescribing in clinical practice.
Findings showed that limited training opportunities, a lack of resources, and reduced confidence in the skills of colleagues were key barriers to successful implementation.
You can read the MABEL Sub Study results paper here https://link.springer.com/article/10.1186/s12904-026-02337-0
In addition to the results papers, protocol papers were published for the CONIFAS-2 and DAMPenD2 studies. Protocol papers describe the rationale and design of a study and help promote transparency in research.
3. CONIFAS-2 – nature intervention for children with ADHD
CONIFAS-2 is supporting children with an ADHD diagnosis, parents and clinicians access the benefits of nature and the outdoors. The intervention is a home-based, family-led intervention delivered with professional third-party telephone support. It encourages daily engagement with nature for at least 10 minutes, including activity cards and supportive psychoeducational elements. Recruitment has now closed, with 70 families taking part in the study.
The study is funded by the NIHR Research for Patient Benefit (RfPB) Programme and sponsored by the Humber NHS Teaching Foundation Trust. The study’s chief investigator is Dr Hannah Armitt.
You can read the CONIFAS-2 protocol paper here https://lnkd.in/eybFbFST.
4. DAMPenD2 – delirium intervention
DAMPenD2 is, internationally, the first national randomised trial of a theoretically informed, co-designed implementation strategy to be conducted in palliative care units. The study aims to improve the Detection, Assessment, Management and Prevention of Delirium in Palliative Care Units. Delirium is common among people approaching the end of life. Around one-third of patients are admitted to a hospice or palliative care unit with delirium, while a further third develop it during their stay. An implementation strategy intervention has been designed to help hospices overcome these challenges and improve adherence to best-practice delirium guidelines. DAMPenD2 has 19 of the 20 sites open and 9 of the 10 intervention sites have received their intervention
The study is funded by the NIHR Health Services and Delivery Research (HSDR) Programme and sponsored by the University of Hull. The study is led by Chief Investigators Professor Mark Pearson and Professor Fliss Murtagh
Other October project headlines:
You can find more about each project here.

Rare disease
1 participant recruited

Breathlessness
12 participants recruited

ADHD
15 participants recruited

Breast cancer
4 participants recruited

Delirium
122 records collected

Prosthetics
4 participants recruited
5 sites opened

